Drug Channels: Key Insights on Drug Prices and Manufacturer Rebates from the New 2015 IMS Report, ims data pharma.#Ims #data #pharma

Posted On May 18 2018 by

ims data pharma DRUG DISAMBIGUATION DETAILS Spending on medicines and invoice price spending both refer to the amounts paid to distributors by their pharmacy or hospital customers. Net price spending is an estimate of the net revenues received by pharmaceutical manufacturers. It therefore reflects estimated rebates, off-invoice discounts, chargebacks, cash discounts, and other price concessions made by manufacturers to distributors, health plans and intermediaries. None of these terms, however, directly correspond to pharmacy revenues, a plan sponsor s drug costs, and national healthcare expenditures. For example: Pharmacy revenues, for example, roughly equate to IMS s spending on medicines for outpatient …


Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients – Pew Charitable Trusts, pharmaceutical industry data.#Pharmaceutical #industry #data

Posted On Mar 8 2018 by

Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients In 2012, the pharmaceutical industry spent more than $27 billion on drug promotion 1 more than $24 billion on marketing to physicians and over $3 billion on advertising to consumers (mainly through television commercials). 2 This approach is designed to promote drug companies’ products by influencing doctors’ prescribing practices. 3 2013 The Pew Charitable Trusts Source: Cegedim Strategic Data, 2012 U.S. Pharmaceutical Company Promotion Spending (2013). Detailing: This marketing approach refers to face-to-face promotional activities directed toward physicians and pharmacy directors. Pharmaceutical representatives typically visit doctors to …


CBC News – Canada s pharma companies disclose payments to doctors for 1st time, pharma data.#Pharma #data

Posted On Mar 6 2018 by

Critics say voluntary move falls short of any real transparency Posted:Jun 20, 2017 9:38 PM ET Canadians were given a glimpse at the millions of dollars doctors receive each year from pharmaceutical companies, when 10 of the country’s largest firms voluntarily disclosed the figures online. But critics are decrying the lack of details around those numbers. Joe Raedle/Getty Images Related Related Stories For the first time, Canadians have been given a glimpse at the millions of dollars doctors receive from pharmaceutical companies each year — though critics say the move stops far short of true transparency. Ten of Canada’s largest …


The 2nd Data Integrity – Protection for Clinical Research Summit – ExL Events, pharma data.#Pharma #data

Posted On Mar 6 2018 by

pharma data The 2nd Data Integrity & Protection For Clinical Research Summit 7–8 December 2017 London, UK / London, United Kingdom The Only European Data Integrity Conference for Clinical Research Professionals Explaining the ICH E6(R2) from Inception to Archival 2nd Data Integrity & Protection for Clinical Research Summit The 2nd Data Integrity & Protection For Clinical Research Summit Data Integrity continues to be a primary goal of clinical research conducted by life science companies. Data can come in an organization in many avenues and is important that any data that is generated for any clinical trial needs to be valid, …


IMS 2015 Use of Medicines report: US sales reach $424, ims data pharma.#Ims #data #pharma

Posted On Mar 5 2018 by

IMS 2015 Use of Medicines report: US sales reach $424.8 billion Double-digit growth (12.2%) for the second year running The annual Use of Medicines report, from the IMS Institute for Healthcare Informatics, comes at a time when drug pricing and revenue growth has been under intensive stress. Perhaps in part for this reason, the Institute is much more careful about distinguishing between ex-manufacturer invoice pricing (which is essentially the price that wholesalers charge their customers) and what it calls “net-price spending,” which accounts for the tens of billions of dollars that pharma companies forgo through rebates, discounts and other off-invoice …


Breaking Down GlaxoSmithKline – s Billion-Dollar Wrongdoing, ims data pharma.#Ims #data #pharma

Posted On Mar 5 2018 by

Breaking Down GlaxoSmithKline s Billion-Dollar Wrongdoing What the drug company did to promote Paxil, Wellbutrin and Avandia illegally — and what it meant for patients In the largest settlement involving a pharmaceutical company, the U.S. Justice Department announced on July 2 that GlaxoSmithKline LLC will pay $3 billion in fines and plead guilty to marketing drugs for unapproved uses and failing to report drug safety information to the U.S. Food and Drug Administration (FDA). The criminal charges involved the illegal marketing of the antidepressants Paxil and Wellbutrin and the withholding of data on the health risks of the diabetes medication …


Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients – Pew Charitable Trusts, pharmaceutical industry data.#Pharmaceutical #industry #data

Posted On Jan 18 2018 by

Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients In 2012, the pharmaceutical industry spent more than $27 billion on drug promotion 1 more than $24 billion on marketing to physicians and over $3 billion on advertising to consumers (mainly through television commercials). 2 This approach is designed to promote drug companies’ products by influencing doctors’ prescribing practices. 3 2013 The Pew Charitable Trusts Source: Cegedim Strategic Data, 2012 U.S. Pharmaceutical Company Promotion Spending (2013). Detailing: This marketing approach refers to face-to-face promotional activities directed toward physicians and pharmacy directors. Pharmaceutical representatives typically visit doctors to …


EFPIA Homepage, pharmaceutical industry data.#Pharmaceutical #industry #data

Posted On Jan 18 2018 by

Illness never sleeps, so neither do we OECD data shows long-term care drive health expenditure, health outcome variations persist The report provides an overview of overall health status in OECD countries, and how medical progress has contributed to longer and healthier lives for. EFPIA welcomes the future location of the EMA decision has been made; now the focus must be on transition. EFPIA congratulates Amsterdam on being selected as the new location for the EMA Incentives, IP and smaller companies – Case story: Vaxeal How Vaxeal wants to change patients’ lives by improving health outcomes 1st European Alliance for Personalised …


Data, Evidence and Access Summit 2017, pharma data.#Pharma #data

Posted On Jan 17 2018 by

8 th Annual Data, Evidence and Access Summit 2018 November 7 – 8th, 2018 | The Inn at Penn | Philadelphia, US Buy the Post Conference Materials Prove Real-Value, Fulfil Data’s Potential And Secure Access Your stakeholders are key – satisfy all their needs at North America’s leading market access and real-world evidence summit. Meeting the needs of payers, patients and decision-makers is a must for any successful pharma company! At Data, Evidence and Access Summit 2017 (Nov 13-14) we know that demonstrating and communicating value is key, no matter which department you’re in. Whether it’s exploring innovative uses of …


Welcome Close Up, Close-Up Internacional, ims data pharma.#Ims #data #pharma

Posted On Jan 17 2018 by

Prescription More than 120 Information and essential Exclusive services technology More than 650 Developer of the first business Business Analyzer® Arbitration due to a breach in an agreement by IMS Health Launch of Business Analyzer ® Audits This is a solution that effectively measures the prescription results of a promotional effort, by systematically investigating the behavior of markets, therapeutic classes, molecules, products, laboratories and their trends. Targeting enables us to choose Prescribers by therapeutic market in order to target promotional activities on physicians and track the results. It enables users to measure productivity by region (District Manager and Representatives), according …